Literature DB >> 30762931

Long noncoding RNA MALAT1 mediates high glucose-induced glomerular endothelial cell injury by epigenetically inhibiting klotho via methyltransferase G9a.

Yebei Li1, Daijin Ren1, Gaosi Xu1.   

Abstract

Several recent reporters have indicated the potential role of long noncoding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) in diabetic nephropathy (DN). However, these studies mainly focus on renal tubular epithelial cells HK-2, the role of MALAT1 in human renal glomerular endothelial cells (HRGECs) remains unclear. Hence, this study aimed to explore the role of MALAT1 in high glucose (HG)-induced HRGECs injury and the underlying epigenetic mechanism. Increased MALAT1 and decreased klotho expression were observed in both renal tissues from DN patients and HG-exposed HRGECs. Furthermore, MALAT1 expression was negatively correlated with klotho expression. Moreover, both MALAT1 knockdown and klotho overexpression significantly abolished the HG-induced HRGECs injury. Importantly, klotho overexpression reversed the MALAT1 overexpression-mediated enhancement of the HG-induced HRGECs injury. In addition, MALAT1 recruited G9a to elevate H3K9me1, which can bind to the klotho promoter and thus inhibited klotho transcription. In conclusion, MALAT recruits methyltransferase G9a to elevate H3K9me1 and epigenetically inhibits klotho expression, and thus mediates HG-induced glomerular endothelial cell injury.
© 2019 IUBMB Life, 1-9, 2019. © 2019 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  G9a; H3K9me1, klotho; MALAT1; diabetic nephropathy

Mesh:

Substances:

Year:  2019        PMID: 30762931     DOI: 10.1002/iub.2009

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  9 in total

1.  Jixuepaidu Tang-1 inhibits epithelial-mesenchymal transition and alleviates renal damage in DN mice through suppressing long non-coding RNA LOC498759.

Authors:  Jing Jin; Zhe Zhang; Jianwu Chen; Yujin Liu; Qianyun Chen; Quansheng Wang
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

Review 2.  Epigenetics in kidney diseases.

Authors:  Hao Ding; Lu Zhang; Qian Yang; Xiaoqin Zhang; Xiaogang Li
Journal:  Adv Clin Chem       Date:  2020-10-21       Impact factor: 6.303

Review 3.  Histone Lysine Methylation Modification and Its Role in Vascular Calcification.

Authors:  Ye-Chi Cao; Su-Kang Shan; Bei Guo; Chang-Chun Li; Fu-Xing-Zi Li; Ming-Hui Zheng; Qiu-Shuang Xu; Yi Wang; Li-Min Lei; Ke-Xin Tang; Wen-Lu Ou-Yang; Jia-Yue Duan; Yun-Yun Wu; Muhammad Hasnain Ehsan Ullah; Zhi-Ang Zhou; Feng Xu; Xiao Lin; Feng Wu; Xiao-Bo Liao; Ling-Qing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

Review 4.  Epigenetic modifications of Klotho expression in kidney diseases.

Authors:  Jinkun Xia; Wangsen Cao
Journal:  J Mol Med (Berl)       Date:  2021-02-06       Impact factor: 4.599

Review 5.  Long Non-Coding RNA Regulation of Epigenetics in Vascular Cells.

Authors:  Hester Garratt; Robert Ashburn; Miron Sopić; Antonella Nogara; Andrea Caporali; Tijana Mitić
Journal:  Noncoding RNA       Date:  2021-09-23

6.  LncRNA ZEB1-AS1 inhibits renal fibrosis in diabetic nephropathy by regulating the miR-217/MAFB axis.

Authors:  Yan Song; Chunxia Miao; Jianwen Wang
Journal:  RSC Adv       Date:  2019-09-25       Impact factor: 4.036

7.  lncRNA MALAT1 Promotes Diabetic Nephropathy Progression via miR-15b-5p/TLR4 Signaling Axis.

Authors:  Zijun Yang; Dongxu Song; Yulin Wang; Lin Tang
Journal:  J Immunol Res       Date:  2022-07-21       Impact factor: 4.493

Review 8.  Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications.

Authors:  Vinay Singh Tanwar; Marpadga A Reddy; Rama Natarajan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

Review 9.  The Dynamics and Plasticity of Epigenetics in Diabetic Kidney Disease: Therapeutic Applications Vis-à-Vis.

Authors:  Feng-Chih Kuo; Chia-Ter Chao; Shih-Hua Lin
Journal:  Int J Mol Sci       Date:  2022-01-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.